

Risk of Severe Arboviral Disease in Patients Receiving B Cell-Depleting or Modulating Medications

Media Disclaimer: *The Pennsylvania Health Alert Network (PA-HAN) provides timely information on emerging public health issues to state and local public health agencies, hospitals, emergency management officials, and other health care providers. These messages are intended to inform and support clinical work and should not be treated as news releases. If members of the media have questions about a PA-HAN, contact the DOH Office of Communications at ra-dhpressoffice@pa.gov.*

DATE:	8/18/2026
TO:	Health Alert Network
FROM:	Debra L. Bogen, MD, FAAP, Secretary of Health
SUBJECT:	Risk of Severe Arboviral Disease in Patients Receiving B Cell-Depleting or Modulating Medications
DISTRIBUTION:	Statewide
LOCATION:	Statewide
STREET ADDRESS:	n/a
COUNTY:	n/a
MUNICIPALITY:	n/a
ZIP CODE:	n/a

This transmission is a “Health Advisory,” and provides important information for a specific incident or situation; may not require immediate action.

HOSPITALS: PLEASE SHARE WITH ALL MEDICAL, PEDIATRIC, NURSING AND LABORATORY STAFF IN YOUR HOSPITAL; **EMS COUNCILS:** PLEASE DISTRIBUTE AS APPROPRIATE; **FQHCs:** PLEASE DISTRIBUTE AS APPROPRIATE; **LOCAL HEALTH JURISDICTIONS:** PLEASE DISTRIBUTE AS APPROPRIATE; **PROFESSIONAL ORGANIZATIONS:** PLEASE DISTRIBUTE TO YOUR MEMBERSHIP; **LONG-TERM CARE FACILITIES:** PLEASE SHARE WITH ALL MEDICAL, INFECTION CONTROL, AND NURSING STAFF IN YOUR FACILITY

SUMMARY

- There is a risk of severe arboviral neuroinvasive disease among patients who are receiving B cell-depleting or B cell-modulating medications, particularly anti-CD20 monoclonal antibodies (mAbs).
- Health care providers should have an awareness of this risk so they can provide education to patients on how to protect themselves against the bites of mosquitoes and ticks and perform the appropriate molecular arboviral testing in immunocompromised patients.
- For questions, please call your local health department or DOH at 877-PA-HEALTH.

BACKGROUND

Arboviruses are RNA viruses transmitted by biting arthropods, most commonly mosquitoes and ticks, which are most active during late spring through early fall. In Pennsylvania, West Nile virus

is the most commonly reported locally-acquired arboviral disease, but others include St. Louis encephalitis virus, eastern equine encephalitis virus, Jamestown Canyon virus, La Crosse encephalitis virus, and Powassan virus. Although most arboviral infections are subclinical, symptomatic arboviral disease typically presents as acute febrile or neurologic illness (e.g., aseptic meningitis, encephalitis, or acute flaccid myelitis). The incubation period is typically days to weeks from arthropod bite to onset of symptoms and can be longer in persons who are immunocompromised.

Medications that deplete B cells or modulate B cell function, which are used for treating B cell malignancies, many autoimmune conditions, and transplant rejection, can increase the risk of severe arboviral disease. B cell-depleting monoclonal antibodies (mAbs) targeting the CD20 cell surface antigen have been associated with a [growing number of reports of severe arboviral neuroinvasive disease](#) in patients on these medications. Health professionals and the public should be aware of this information because the United States had an early and strong start to this year's West Nile virus season and many weeks of the arbovirus transmission season remain.

Anti-CD20 mAbs currently [approved in the United States](#) include rituximab and biosimilars, ocrelizumab, ofatumumab, ublituximab, obinutuzumab, and ibritumomab tiuxetan. Among published case reports of arboviral neuroinvasive disease in patients on anti-CD20 mAbs, overall mortality was approximately 40%, and most survivors experienced long-term neurologic sequelae. [West Nile virus](#) was the most common infecting arbovirus in these case reports. Less common or regionally focal viruses in the United States, such as [eastern equine encephalitis virus](#), [Powassan virus](#), [Jamestown Canyon virus](#), [La Crosse virus](#), [Cache Valley virus](#), and Potosi virus, have also caused severe disease in these patients.

[In a recent CDC case series](#), a novel clinical presentation of chronic, neurodegenerative encephalitis developing over months to years has been described in at least five patients outside of Pennsylvania receiving rituximab who were infected with an orthobunyavirus, including Jamestown Canyon virus, Cache Valley virus, or Potosi virus. All patients died; diagnoses were delayed because of unrecognized infection and rare or unexpected pathogens requiring specialized diagnostic testing.

Because patients receiving anti-CD20 mAbs or other medications that deplete B cells (e.g., anti-CD38 mAbs) or modulate B cell function (e.g., B cell activating factor inhibitors) might not form antibodies against a new infection, diagnosis of arboviral infection often requires molecular rather than serologic testing. Molecular testing typically includes virus-specific RT-PCR or metagenomic next-generation sequencing (mNGS) to detect viral RNA in specimens such as serum, plasma, cerebrospinal fluid (CSF), whole blood, or tissue. Clinicians can contact their state or local health departments for consultation on appropriate testing to perform based on the patient's medical conditions and medications.

There are no approved treatments, prophylactic agents, or human vaccines to prevent arboviral diseases endemic to the United States. Therefore, it is critical that patients receiving medications that deplete or reduce B cell function be advised to use [personal protective measures to prevent mosquito and tick bites](#).

RECOMMENDATIONS FOR CLINICIANS

- When prescribing any immunosuppressive medications or caring for patients taking any immunosuppressive medication, particularly B cell-depleting mAbs, [educate patients about the risk of severe arboviral disease and advise them to take measures to prevent mosquito and tick bites](#).
- Be aware that patients with an arboviral disease who are immunocompromised can have a prolonged incubation period or an atypical course and might not present with illness during the usual months when mosquitoes and ticks are active (i.e., May through November in the United States).
- Take a thorough exposure and travel history for patients presenting with a febrile or neurologic illness.
- When an arboviral infection is suspected in a patient receiving B cell-depleting mAbs, preferentially order molecular testing (i.e., RT-PCR or mNGS).
 - Immunocompromised patients, particularly those receiving B cell-depleting mAbs, can have prolonged viremia and delayed or absent antibody responses.
 - Preferred specimen type(s) depend on the clinical presentation and laboratory conducting the testing. Molecular tests are available from some commercial and public health laboratories.
 - Serologic testing of serum or CSF for virus-specific IgM antibodies should be ordered only for patients who are immunocompetent or receiving immunomodulating drugs that do not substantially suppress antibody production.
 - Contact your local health department or DOH at 877-PA-HEALTH for consultation on the optimal testing approach.
 - See the [diagnostic testing algorithm for suspected West Nile virus disease](#) for more details.

RECOMMENDATIONS TO SHARE WITH PATIENTS

- [Take steps to prevent mosquito and tick bites](#) to lower the risk of vector-borne diseases including arboviral infections:
 - Use Environmental Protection Agency (EPA)-registered insect repellent.
 - Wear loose-fitting, long-sleeved shirts and pants when outdoors.
 - Use screens on windows and doors or use air conditioning to keep mosquitoes outside.
 - Treat clothing and gear with products containing 0.5% permethrin.
 - Avoid wooded and brushy areas with high grass and leaf litter where ticks live.
 - Check clothing, body, gear, and pets for ticks when returning indoors.
 - Shower soon after being outdoors to check for ticks and help wash off unattached ticks.
- If you are taking a medication that suppresses your immune system, know that you could be at higher risk of having severe illness from an infection, including arboviral infections.
- Notify your healthcare provider if you have concerning changes to your health, such as persistent headaches, fever, body aches, weakness, loss of balance, or confusion.
- Tell your health care provider about any recent travel or exposure to mosquitoes or ticks and remind them of the medications you are taking.
- Be aware of what mosquito- and tickborne viral diseases might be circulating in your area by visiting the [DOH vectorborne webpage](#) and the [DEP Mosquito-borne Disease Control Program webpage](#).

DIAGNOSIS OF ARBOVIRAL INFECTIONS

For most arboviral infections, serology can facilitate diagnosis. WNV diagnosis is usually serological, by detection of WNV-specific IgM antibody in serum or CSF. **WNV IgM may not be detectable until day 8 of illness or longer if patient is immunocompromised**. Specimens collected less than 8 days after symptom onset may be negative for IgM, and testing should be repeated 2-3 weeks later on immunocompetent patient. If patient is immunocompromised, RT-PCR testing should also be performed. Whole blood and urine specimens are more sensitive for WNV RT-PCR than serum or CSF; however, serum and CSF are needed to perform serologic testing to exclude infection if RT-PCR is negative.

Specimens collected from patients with suspected WNV can be submitted to the DOH Bureau of Laboratories (BOL). Instructions for submitting specimens can be found at [Arbovirus testing form](#).

Requests for testing of SLEV, EEEV, JCV, LACV, and POWV can also be sent to DOH BOL using the arbovirus testing form. These specimens are then sent to CDC (via BOL) for testing and the same instructions apply for collection and submission. At least 1mL of serum or CSF is needed for each arbovirus testing request.

For questions, please call your local health department or DOH at 877-PA- HEALTH.

Individuals interested in receiving future PA-HANs can register at:
<https://signup.e2ma.net/signup/2096210/2061850/>.

Categories of Health Alert messages:

Health Alert: conveys the highest level of importance; warrants immediate action or attention.

Health Advisory: provides important information for a specific incident or situation; may not require immediate action.

Health Update: provides updated information regarding an incident or situation; unlikely to require immediate action.

This information is current as of August 18, 2026 but may be modified in the future.
--